UnitedHealth Group reported robust third-quarter results, with revenues up 12% to $56.6 billion and adjusted EPS increasing 28% to $3.41. The company raised its full-year adjusted EPS guidance to approach $12.80, indicating confidence in continued growth. Management's positive tone and strong performance across all divisions suggest a favorable short-term impact on the stock price.

[1]